Flupirtine
Aliases: Pruf, W-2964, D-9998, Awegal, Efiret
Summary
Flupirtine is a pyridine derivative that is in clinical use as a nonopioid analgesic. It was approved for the treatment of pain in 1984 in Europe. It is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment of fibromyalgia.
Dose Information
Light
Common
Strong
Heavy
Onset, Duration & After-effects
| ROA | Onset | Comeup | Peak | Offset |
|---|---|---|---|---|
| Oral | 30-60 min | 30-60 min | 1-2 hrs | 4-6 hrs |
Tolerance
Build-up
develops over 1–4 weeks of regular use
Reset
days to weeks depending on duration of use
Tolerance Decay
Full tolerance
3d
Half tolerance
8d
Baseline
~14d
Effects
Positive
- Pain Relief
- Muscle Relaxation
- Physical euphoria
- Pain relief
Negative
- Fatigue
- Motor impairment
- Respiratory depression
- Nausea
- Sedation
- Itchiness
Positive
- Reduced anxiety
- Anxiety suppression
- Cognitive euphoria
- Dream potentiation
- Focus enhancement
- Motivation enhancement
- Euphoria
Negative
- Dizziness
- Drowsiness
- Constipation
Positive
- Increased music appreciation
Negative
- Appetite suppression
- Double vision
- Light sensitivity
- Disinhibition
- Acuity suppression
- Visual acuity suppression
- Dulled perception
- Internal hallucination
- Perception of bodily heaviness
Flupirtine's nerd page
Pharmacology, chemical data, effect profiles, and more
→